Nutcracker Therapeutics is developing and producing RNA therapeutics as fast as possible using microfluidic technology. RNA therapeutics have many advantages - versatility, speed, efficacy and safety. However, manufacturing has hindered the production of RNA therapeutics for multiple diseases. Through the use of their proprietary Biochip-based manufacturing platform, Nutcracker is using biochemistry, nanoparticle delivery and microfluidic engineering to automate and scale RNA therapeutics. As Nutcracker is focused on the technology, they are partnering with experts in different diseases to bring their products to patients. Currently, Nutcracker has 3 programs close to clinical trials for different cancers.

<p>Nutcracker Therapeutics is developing and producing RNA therapeutics as fast as possible using microfluidic technology. RNA therapeutics have many advantages - versatility, speed, efficacy and safety. However, manufacturing has hindered the production of RNA therapeutics for multiple diseases. Through the use of their proprietary Biochip-based manufacturing platform, Nutcracker is using biochemistry, nanoparticle delivery and microfluidic engineering to automate and scale RNA therapeutics. As Nutcracker is focused on the technology, they are partnering with experts in different diseases to bring their products to patients. Currently, Nutcracker has 3 programs close to clinical trials for different cancers.</p>


Nutcracker Therapeutics

Senior Manufacturing Engineer

Bioprocess Technician II - Manufacturing

CNC Machinist III

Three members of our team Gad Berdugo, Nicole Fay, and Colin McKinlay will be attending TIDES USA next week! Be sure to catch Colin's talk on mRNA manufacturing with our platform, the NMU-Symphony™, at 1:30 PM PST on May 21.

We had a blast at our annual company holiday party! We're wishing everyone who celebrates a happy holiday season.

 MRNA therapeutic compositions 

 Nutcracker Therapeutics Appoints Industry Veteran Angela Peters as Chief Human Resources Officer 

 Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers 

Achieving Flexibility In RNA Drug Manufacturing With Microfluidics

 Customized codon sequences 

Nutcracker announces key C-suite hires, unveils pipeline - The Pharma Letter

 The Crunchbase News Briefing: Wed., Sept. 23 

 Nutcracker Therapeutics CEO Dr. Igor Khandros Retires as Company Continues Evolution as an RNA Therapeutics CRDMO 

 Nutcracker Therapeutics Adds Dr. Thomas J. Dietz to Board of Directors 

 Compositions and methods of mrna therapeutics 

We're thrilled to be in Boston for this year's PODD conference! Colin McKinlay will be giving a talk on our peptoid-based Nutshell® delivery vehicles.

Nutcracker Therapeutics to Unveil New Drug Candidate NTX-472 at ASCO 2024 and Participate in the Sachs Oncology Innovation Forum - Business Wire

Modification of mRNA-encoded HPV16 antigens to include endolysosomal trafficking domains drives cross-presentation and results in superior in vivo and ex vivo antigen-specific responses

 mRNA treatment nanoparticles 

We've got a busy May coming up! Colin McKinlay and Babak Sanii will be showcasing our NMU-Symphony™ platform for the manufacture of personalized cancer therapeutics with talks at two leading industry conferences: TIDES USA and the 3rd mRNA Process Development & Manufacturing Summit Europe!

Learn more here: https://lnkd.in/eiV-4M9k

We'd love to see you there! Contact us here:  https://lnkd.in/efKCJGAR

Nutcracker snags $167M series C to develop 'push-button ...

 Mrna therapeutic compositions 

Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024 - Business Wire

 Nutcracker Therapeutics to Showcase NMU-Symphony™ Platform for Personalized Cancer Therapeutics at Leading Industry Conferences 

 Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch as Chief Scientific Officer 

Nutcracker raises $60M to fund 'push-button' mRNA therapeutics platform - BioWorld MedTech

Delivering a New “Post-COVID” Generation of RNA Therapeutics


              Tackling The Standardization Issue For mRNA Therapeutics
            

Nutcracker Therapeutics lays off 12 employees less than 18 months after $167M series C - Fierce Biotech


              Addressing Challenges in mRNA and LNP Manufacturing (Part One)
            

 Nutcracker Therapeutics on LinkedIn: We are so excited that our very own Oreanna Thomas will be participating… 

Biotech naming trends bypass 'buzzwords and business speak' to build whimsical, memorable brands - Fierce Biotech

We're delighted to have Cynthia Collins serve as our executive chair! Cynthia has been a member of our board of directors for nearly two years, and has more than four decades of experience in the pharmaceutical and biotech industry. Thank you for your leadership, Cynthia!

 Nutcracker Therapeutics' Research Partner, the University of California, San Francisco, Presents Foundational Prostate ... 

 Mrna therapies including sirp-alpha 

We're hiring! We have three exciting openings in our manufacturing team: CNC Machinist III, Senior Manufacturing Engineer, and Bioprocess Technician II.

We're looking for skilled engineers who are driven to discover, create, and inspire something that moves science and technology forward.

Interested? Apply by visiting our website: https://lnkd.in/ektf6CbD


Samuel Deutsch recently spoke to Pharma's Almanac about new opportunities that are emerging for mRNA technology, along with other industry leaders! 

Check out what they had to say here:  https://lnkd.in/eKzhv5Mz

#mRNATherapeutics #RNAResearch

 Nutcracker Therapeutics lays off 12 employees less than 18 months after $167M series C 

Global mRNA Therapeutics Market Outlook Forecasts to 2030 - Spherical Insights

Igor Khandros and Gad Berdugo will be in Boston at the 12th International mRNA Health Conference this week! We'd love to see you there!

Nutcracker snags $167M series C to develop 'push-button' RNA manufacturing, signs on former Gilead CFO - Fierce Biotech

 Ethyl modified rna caps and methods of use 

 Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the ... 

Nutcracker Therapeutics Announces $60 Million Series B Financing to Advance mRNA Therapeutics Produced on Transformational Biochip-Based ACORN Platform - PR Newswire


              Exploring Opportunities for LNP Delivery in mRNA
            

We're thrilled to announce that we are launching new CRDMO capabilities to provide next generation biomanufacturing solutions for RNA drug developers! The services will leverage our Nutcracker® Manufacturing Unit to provide flexible solutions to scale down RNA production for personalized therapeutics or scale up for clinical trials. 
Learn more here: https://lnkd.in/ent6jWrY

New COO, CBO at Nutcracker - BioCentury

Nutcracker Therapeutics Presents Precision Biomanufacturing and CRDMO Solutions at the 2024 Personalized Cancer Vaccine Summit - Yahoo Finance

Interview: Sam Deutsch, Chief Scientific Officer, Nutcracker Therapeutics

Local delivery of mRNA immunotherapy encoding HPV16 antigen, IL-12, and LIGHT/TNFSF14 results in superior immunogenicity and tumor clearance in a murine model of HPV16-driven cancer

 Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024 

Biopharmaceuticals: Simplifying Complexity With mRNA - The Medicine Maker

 Rna cap analogs and methods of use 

Nutcracker Therapeutics CEO Dr. Igor Khandros Retires as Company Continues Evolution as an RNA Therapeutics CRDMO - Business Wire

NTX-470, a novel multispecific T cell engager expressed from mRNA targets PSMA and STEAP1 prostate cancer antigens to generate enhanced functional activity

 Mrna treatment nanoparticles 

We're in Berlin for the 3rd annual mRNA Process Development and Manufacturing Summit Europe! Babak Sanii recently gave a talk on manufacturing personalized cancer therapeutics with NMU-Symphony™, our end-to-end microfluidic manufacturing platform, and presented a poster on our ProcessVision™ sensors to measure microfluidic pressure, concentration, and particle-size.

Learn more at the conference website: https://lnkd.in/efpnU8-C

#mRNAManufacturing

Why RNA Is Good For Business

We're proud to announce that we'll be back in Boston next week as an expertise partner at the Personalized Cancer Vaccine Summit! Be sure to stop by at booth 1 to say hi! 
Learn more here: https://lnkd.in/eRa_ptpE

Nutcracker: RNA Design, Delivery and Manufacturing Under One Roof

1359 NTX-0471, engineered multivalent SIRPa and bispecific SIRPa-antiCCR4 molecules demonstrate superior activity providing path for mRNA expressed in-vivo biologics

Top 10 RNA-Based Biopharmas - Genetic Engineering & Biotechnology News

Samuel Deutsch will be presenting this week at the Personalized Cancer Vaccine Summit! His talk will focus on the manufacturing capabilities of our Nutcracker® Manufacturing Unit to create scalable and personalized medicines, including personalized cancer vaccines. 
Learn more here: https://lnkd.in/eRa_ptpE

 News - Business Financing, Nutcracker Therapeutics 

Nutcracker Therapeutics Raises $167 Million in Series C Financing to Advance its mRNA Therapeutics and First-of-its-Kind Biochip-based Manufacturing Platform - Business Wire

Thank you Igor Khandros for seven years of guidance and leadership as our CEO. We're thrilled that Igor will continue guiding Nutcracker as a member of our board of directors. Here's to an incredible career and a happy retirement! 
https://lnkd.in/eg4REnfB

Longtime East Bay entrepreneur eyes streamlined RNA drugs, raises $60M - The Business Journals

Enhanced membrane stability of mRNA nanoparticle derived TNFSF14 results in superior T-cell and NK cell stimulation

 Chutes & Ladders—Former Celgene CEO Alles takes the top ... 

 Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer 

 Nutcracker Therapeutics Raises $167M in Series C 

Nutcracker Therapeutics Announces Publication in ACS Nano Demonstrating the Therapeutic Viability of Nutshell - Business Wire

Nicole Fay is at the Future of Biotech Summit as a part of the NYC Deep Tech Week! She'll be giving a talk on delivering personalized therapies with microfluidic manufacturing solutions, and will be serving on the panel for nanotechnology, precision gene therapy, and the future of curative medicine.

134 mNTX-250, a novel multimodal HPV-16 mRNA-based therapeutic, induces potent anti-tumor responses and establishes HPV-16 specific immune memory

 Nutcracker raises $60M to fund 'push-button' mRNA therapeutics platform 

Today reminds us to empower young women to pursue a career in STEM and celebrate the contributions women have made towards scientific advancement. A special thank you to all of the women of Nutcracker for all that you do! #WomenInScience #WomenInSTEM #ScienceForAll

 The Legend Steve Gorlins Golden Rules 

BioSpace Movers & Shakers: SOTIO, Voyager, Nutcracker and More - BioSpace

Nutcracker Therapeutics raises $167m to advance mRNA biochip-based manufacturing platform - BioPharma-Reporter.com

 Microfluidic apparatus and methods of use thereof 

Three members of our team, Samuel Deutsch, Nicole Fay, and Gad Berdugo, will be at the Personalized Cancer Vaccine Summit this week! Catch Sam's talk on Wednesday December 4 at 4:30 p.m. ET, focusing on the manufacturing capabilities of our Nutcracker® Manufacturing Unit to create scalable and personalized medicines, including personalized cancer vaccines. 
Learn more here: https://lnkd.in/eRa_ptpE

 Nutcracker Therapeutics Presents Precision Biomanufacturing and CRDMO Solutions at the 2024 Personalized Cancer Vaccine Summit 

Nutcracker Therapeutics to Showcase NMU-Symphony™ Platform for Personalized Cancer Therapeutics at Leading Industry Conferences - Business Wire

Chutes & Ladders—Yet another exec departs CRISPR Tx - Fierce Biotech

Why RNA Is Good For Business - Life Science Leader Magazine

There Is a Need for Better CIN Therapies to Prevent Cervical Cancer

 7 Companies Doing DNA Synthesis for Medical R&D 

We had a great time connecting with our peers at the Personalized Cancer Vaccine Summit last week! We're proud to have sponsored such a remarkable event that provided a platform for industry leaders to communicate and share their work.

 Apparatuses and methods for measuring dna/rna production in biochips 

Mapping of shared tumor antigen reactivity with nanoparticle encapsulated mRNA in prostate cancer patients

Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers - Business Wire

RNA Pioneer and Former Editas CEO Joins Codexis Board: Strategic Move for RNA Therapeutics Push - Stock Titan

 Nutcracker Therapeutics to Unveil New Drug Candidate NTX-472 at ASCO 2024 and Participate in the Sachs Oncology ... 


                Tackling The Standardization Issue For mRNA Therapeutics
              

Nutcracker Therapeutics

Business:

Drug notes:

About: